Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in moderate to severe plaque psoriasis in Chinese subjects
NCT06122649Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apremilast in plaque psoriasis, sponsored by Amgen. Started Nov 2023; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06122649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122649.